Evidence Around BCL2 Inhibitors for Patients with t(11;14) Translocation in MM

Video

Drs Shaji Kumar and Jonathan Kaufman review the BELLINI trial, as well as provide an overview of other investigational studies of BCL2 inhibitors for the treatment of patients with t(11;14) translocation with relapsed refractory multiple myeloma.

Related Videos
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Video 4 - "Challenges in Adopting Targeted Therapies for BRAF Alterations"
Video 3 - "BRAF V600E Mutant Ganglioglioma"
Michael Leung, PharmD, an expert on colorectal cancer
A panel of 4 experts on colorectal cancer
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Related Content
Erika P. Hamilton, MD

Antibody-Drug Conjugates Expand HER2+ Breast Cancer Treatment Options

December 5th 2022
Article
Peter Gibbs, MBBS, MD, FRACP, a medical oncologist at St Vincent’s Private Hospitals and a professor at the University of Melbourne in Australia

MRD Detection Emerges as a Catalyst for Advances in Colon Cancer

December 5th 2022
Article
DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC

DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC

November 22nd 2022
Article
Shaji Kumar, MD

Biomarker-Directed Therapy in Multiple Myeloma Signals the Future of the Field

September 1st 2022
Article
Treating Patients with Gastric Cancer

Treating Patients with Gastric Cancer

August 25th 2022
Article
Multidisciplinary Management of Patients with Basal Cell Carcinoma

Multidisciplinary Management of Patients with Basal Cell Carcinoma

August 24th 2022
Article